Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of ursodeoxycholic acid to prevent recurrence of Clostridioides difficile infection
2018-001906-27Phase 2Unknown
- Sponsor
- Nottingham University Hospitals
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ursodeoxycholic acid in Clostridioides difficile infection (CDI), sponsored by Nottingham University Hospitals. Primary endpoint: Study completion. Status: unknown.
02
Drugs
ursodeoxycholic acid
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on 2018-001906-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001906-27.